Top of page

Experience

To find Davis Polk deals and cases of particular interest, select filters based on practice, industry, region, lawyer and keyword.

Filters

Tigermed HK$10.7 billion IPO and Hong Kong listing
Davis Polk advised Hangzhou Tigermed Consulting Co., Ltd. in connection with its initial public offering and listing on the Hong Kong Stock Exchange and an international offering in…
BioXcel Therapeutics $200 million stock offering
Davis Polk advised the underwriters in connection with the SEC-registered offering by BioXcel Therapeutics, Inc. of 4,000,000 shares of its common stock. The common stock is listed on the…
Innovent Biologics HK$4.65 billion share placement
Davis Polk advised the sole placing agent for the placement of 56,200,000 new shares and 36,800,000 existing shares in Innovent Biologics, Inc., for an aggregate consideration of…
Nurix Therapeutics $209 million IPO
Davis Polk advised the underwriters in connection with an initial public offering of 11,000,000 shares of common stock of Nurix Therapeutics, Inc. at $19 per share, for total gross proceeds…
Berkeley Lights $204.9 million IPO
Davis Polk advised the underwriters in connection with an initial public offering of 9,315,000 shares of common stock of Berkeley Lights, Inc. at $22.00 per share (which includes the…
Atreca $125 million stock offering
Davis Polk advised the representatives of the several underwriters in connection with a $125 million SEC-registered common stock offering by Atreca, Inc. The common stock is listed on…
InflaRx $50 million at-the-market offering
Davis Polk advised the sales agent in connection with an SEC-registered at-the-market offering by InflaRx N.V. of its shares of common stock for up to an aggregate amount of $50…
Inventiva $108 million U.S. IPO and Nasdaq listing
Davis Polk advised the representatives of the underwriters in connection with an initial public offering of Inventiva S.A.’s 7,478,261 American Depositary Shares. Aggregate gross…
Back to top